LYON, France - EDAP TMS SA (NASDAQ:EDAP), a company specializing in therapeutic ultrasound, will present the final results of its HIFI Study at the upcoming American Urological Association Annual Meeting (AUA 2024) in San Antonio, Texas.
The study is the largest clinical trial to date comparing the outcomes of EDAP's Focal One robotic high intensity focused ultrasound (HIFU) with traditional radical prostatectomy in the treatment of localized prostate cancer.
The HIFI Study encompasses data from 3,328 cases and will be featured in a plenary session titled "HIFI trial: HIFU vs Radical prostatectomy for localized Prostate cancer" on Friday, May 3, 2024. Professor Pascal Rischmann is slated to present the findings at 11:11 AM CDT in the Stars at Night Ballroom of the Henry B. Gonzalez Convention Center.
The AUA Annual Meeting is a premier event for urological professionals, drawing over 11,000 attendees and featuring more than 300 technical exhibitors. It provides a comprehensive platform for education and the exchange of knowledge on the latest advancements in urologic medicine.
EDAP TMS is recognized for its development, manufacture, and distribution of minimally invasive medical devices for the treatment of various pathologies using ultrasound technology. The company's Focal One device is designed to meet the stringent requirements for ideal prostate tissue ablation and is complemented by the ExactVu Micro-Ultrasound device, positioning EDAP TMS as the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer.
The press release also contains forward-looking statements regarding the clinical status and market acceptance of EDAP's HIFU devices and the potential market for its lithotripsy and distribution divisions.
These statements are based on current management expectations and are subject to various risks and uncertainties that could cause actual results to differ materially from those anticipated.
The information presented in this article is based on a press release statement from EDAP TMS SA.
InvestingPro Insights
As EDAP TMS SA (NASDAQ:EDAP) gears up to present pivotal clinical trial results at the AUA 2024, investors and industry observers are closely monitoring the company's financial health and market performance.
With a market capitalization of 265.29 million USD and a negative P/E ratio of -12.74, reflecting the company's current lack of profitability, EDAP's financial landscape is a critical aspect of its overall potential for growth and innovation in the medical device sector.
An important highlight from the InvestingPro data is the company's revenue growth over the last twelve months as of Q4 2023, which stands at a solid 9.64%. This is complemented by an even more impressive quarterly revenue growth of 24.77% for Q4 2023, signaling a positive trajectory in sales and market penetration.
Despite these gains, EDAP's operating income margin remains negative at -27.16%, indicating that the company is still navigating its path towards operational efficiency and profitability.
InvestingPro Tips suggest that while EDAP holds more cash than debt on its balance sheet and liquid assets exceed short-term obligations, analysts do not anticipate the company will be profitable this year. This is a crucial consideration for investors looking at the long-term value and sustainability of the company. Additionally, EDAP does not pay a dividend to shareholders, which may influence investment decisions for those seeking regular income streams.
For readers interested in a deeper analysis of EDAP TMS SA, InvestingPro offers additional insights and metrics. There are more InvestingPro Tips available, which can be accessed at https://www.investing.com/pro/EDAP. To further enhance your investment research, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, providing a more comprehensive understanding of EDAP's financial and operational standing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.